Top

Familial Cancer

Published in:

Open Access 01-07-2018 | Letter to the Editor

Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations

Authors: Jacopo Azzollini, Milena Mariani, Bernard Peissel, Siranoush Manoukian

Published in: Familial Cancer | Issue 3/2018

Excerpt

Dear Editor, …

O’Shea R, Clarke R, Berkley E, Giffney C, Farrell M, O’Donovan E, Gallagher DJ (2017) Next generation sequencing is informing phenotype: a TP53 example. Fam Cancer. doi:10.1007/s10689-017-0002-1 CrossRef

Merlo DF, Ceppi M, Filiberti R, Bocchini V, Znaor A, Gamulin M, Primic-Žakelj M, Bruzzi P, Bouchardy C, Fucic A, AIRTUM WG (2012) Breast cancer incidence trends in European women aged 20–39 years at diagnosis. Breast Cancer Res Treat 134:363–370. doi:10.1007/s10549-012-2031-7 CrossRefPubMed

Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, Gauthier-Villars M, Stoppa-Lyonnet D, Consolino E, Brugières L, Caron O, Benusiglio PR, Bressac-de Paillerets B, Bonadona V, Bonaïti-Pellié C, Tinat J, Baert-Desurmont S, Frebourg T (2015) Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33:2345–2352. doi:10.1200/JCO.2014.59.5728 CrossRefPubMed

McCuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod SA, Malkin D (2012) Routine TP53 testing for breast cancer under age 30: ready for prime time? Fam Cancer 11:607–613. doi:10.1007/s10689-012-9557-z CrossRefPubMed

Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, Ghadirian P, Robidoux A, Londono J, Vasquez G, Gomes M, Costa MM, Dimitrakakis C, Gutierrez G, Pilarski R, Royer R, Narod SA (2009) The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer 8:563–567. doi:10.1007/s10689-009-9287-z CrossRefPubMed

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–24. doi:10.1038/gim.2015.30 CrossRefPubMedPubMedCentral

Title: Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations
Authors: Jacopo Azzollini
Milena Mariani
Bernard Peissel
Siranoush Manoukian
Publication date: 01-07-2018
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 3/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-017-0020-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2018

Penetrance of a rare familial mutation predisposing to papillary thyroid cancer

Screening for germline mutations in mismatch repair genes in patients with Lynch syndrome by next generation sequencing

Ectopic, retroperitoneal adrenocortical carcinoma in the setting of Lynch syndrome

Cost-effectiveness evaluation of pre-counseling telephone interviews before face-to-face genetic counseling in cancer genetics

Excluding Lynch syndrome in a female patient with metachronous DNA mismatch repair deficient colon- and ovarian cancer

Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer